

# Gazetteer Trials Newsletter

Welcome to this short presentation about the Weekly [Gazetteer Trials Newsletter](#).

The [Gazetteer Trial Newsletter](#)

Includes

INDUSTRY-SPONSORED TRIALS listed with  
[www.clinicaltrials.gov](http://www.clinicaltrials.gov)

The trials were listed FOR THE FIRST TIME during the past  
week

All trials listed are in the PLANNING STAGE

# Gazetteer Trials Newsletter

The [Gazetteer Trial Newsletter](#) is useful ...

(A) in following the new drug development in a certain therapeutic area or for a certain disease, or

(B) in identifying potential interesting clinical trials.

Both scenarios will be covered in this presentation.

# Gazetteer Trials Newsletter


This **left screen shot** is from the home page of ClinicalTrialMagnifier/go

This webpage includes an alphabetic list of the therapeutic areas and diseases of the trials identified during the past week.

A click on **Download** will taken you to a new webpage i.e ClinicalTrialMagnifier/trial

The **right screen shot** shows a part of this website. You are at present reviewing the **Review Tips** posted here.

On the following pages of this presentation we will explore the Excels file **Gazetteer Trials: 2020-November-19**.



Past Week's Review

November 19, 2020

[Download](#)

[DISEASE / CONDITION](#)

ALLERGY ECZEMA/DERMATITIS  
ANEST PAIN ACUTE  
ANEST PAIN CHRONIC  
CARDIO CARDIOMYOP/FAILURE  
CARDIO CORONARY/ISCHEMIC  
CARDIO CORONARY/ISCHEMIC  
CARDIO DISEASE  
CARDIO HEART DISEASE  
CARDIO HYPERTENSION  
CARDIO PERIPH VASC  
CARDIO PERIPH VASC  
CARDIO STROKE  
ENDO DIABETES

## *Gazetteer Trials Newsletter*

The *Gazetteer Trials Newsletter* includes **ALL INDUSTRY-SPONSORED TRIALS** that have been **LISTED FOR THE FIRST TIME** and still being in the **PLANNING STAGE**.

The list is sorted by Area / Disease.

The list can be re-sorted.

[Review Tips](#)

## [Newsletter Archive](#)

Note that the status of a trial may have changed from previous Gazetteer Issues.

[Excel Downloads](#)

[Gazetteer Trials: 2020-November-19](#)

[Gazetteer Trials: 2020-November-12](#)

# Gazetteer Trials Newsletter

## Excels file **Gazetteer Trials: 2020-November-19.**

**Screen shot:** All Excel columns are included in this screen shot.

In total 87 new industry-sponsored trials were identified and listed this week.

As seen from the listing nine trials are in Cardiology.

Some Sponsors are well-known while other Sponsors are less know.

The Excel file can be sorted as you wish, e.g. by PHASE in order to identify Phase I trials.

	A	B	C	D	E	F	G	H	I
1	IDCTGOV (Link)	SPONOSOR	AREA / DISEASE	TEST PRODUCT	STATUS	PHASE	SUBJECTS GLOBAL (N)	MIN AGE	MAX AGE
2	<a href="#">NCT04626297</a>	ELI LILLY	ALLERGY ECZEMA/DERMATITIS	DRUG	1. PLANNING	3	240	18 YEARS	55 YEARS
3	<a href="#">NCT04622735</a>	UNITHER	ANEST PAIN ACUTE	COMBINATION	1. PLANNING	3	321	18 YEARS	65 YEARS
4	<a href="#">NCT04630158</a>	NOVARTIS	ANEST PAIN CHRONIC	OTHER	1. PLANNING	2	150	18 YEARS	N/A
5	<a href="#">NCT04630067</a>	ASTRAZENECA	CARDIO CARDIOMYOP/FAILURE	DRUG	1. PLANNING	1	104	18 YEARS	75 YEARS
6	<a href="#">NCT04625764</a>	CYTOSORBENTS	CARDIO CORONARY/ISCHEMIC	PROCEDURE	1. PLANNING	NA	30	18 YEARS	N/A
7	<a href="#">NCT04626687</a>	ACOTEC	CARDIO CORONARY/ISCHEMIC	DEVICE	1. PLANNING	NA	230	18 YEARS	80 YEARS
8	<a href="#">NCT04627207</a>	CHONG KUN DANG	CARDIO DISEASE	DRUG	1. PLANNING	1	51	19 YEARS	54 YEARS
9	<a href="#">NCT04630704</a>	PEDRA	CARDIO HEART DISEASE	DEVICE	1. PLANNING		50	40 YEARS	90 YEARS
10	<a href="#">NCT04626245</a>	LIFESPAN	CARDIO HYPERTENSION	BEHAVIORAL	1. PLANNING	NA	150	18 YEARS	N/A
11	<a href="#">NCT04625660</a>	PQ BYPASS	CARDIO PERIPH VASC	DEVICE	1. PLANNING	NA	70	18 YEARS	90 YEARS
12	<a href="#">NCT04627870</a>	ACOTEC	CARDIO PERIPH VASC	DEVICE	1. PLANNING	NA	60	18 YEARS	80 YEARS
13	<a href="#">NCT04622644</a>	UMBRIA BIO.	CARDIO STROKE	DEVICE	1. PLANNING	NA	60	18 YEARS	N/A
14	<a href="#">NCT04628481</a>	DOMPE	ENDO DIABETES	DRUG	1. PLANNING	3	327	14 YEARS	45 YEARS
15	<a href="#">NCT04623957</a>	PANSATORI	ENT TINNITUS	DEVICE	1. PLANNING	NA	35	18 YEARS	N/A
16	<a href="#">NCT04624841</a>	HAMAD MEDICAL	GI BILIARY DISEASE	DRUG	1. PLANNING	4	80	18 YEARS	N/A
17	<a href="#">NCT04622358</a>	ADDPHARMA	GI ESOPHAGITIS/REFLUX	DRUG	1. PLANNING	1	40	19 YEARS	50 YEARS

# Gazetteer Trials Newsletter

## Three issues to consider:

1. The duration between posting a trial with [clinicaltrials.gov](http://clinicaltrials.gov) to the initiation of the trial varies – from weeks to years.
2. The trial Sponsor can have the headquarter in any country.
3. The trials listed are under planning so we do not know where the trials will be conducted – e.g. in the US or elsewhere. As an illustration the Table shows the distribution of the number of industry-sponsored phase II/III trial sites – over a two year period. All trials were registered with [clinicaltrials.gov](http://clinicaltrials.gov).

COUNTRY	RANK	SITES (N)	SITES (%)
UNITED STATES	1	93,951	36.91
JAPAN	2	13,894	5.46
CHINA	3	10,485	4.12
GERMANY	4	10,356	4.07
SPAIN	5	10,159	3.99
POLAND	6	7,914	3.11
FRANCE	7	7,833	3.08
RUSSIA	8	7,740	3.04
CANADA	9	7,559	2.97
ITALY	10	7,271	2.86
UNITED KINGDOM	11	6,987	2.74
KOREA, SOUTH	12	5,399	2.12
AUSTRALIA	13	5,046	1.98
UKRAINE	14	3,893	1.53
HUNGARY	15	3,729	1.46
BRAZIL	16	3,583	1.41
CZECH REPUBLIC	17	3,261	1.28
BELGIUM	18	3,122	1.23
ARGENTINA	19	3,076	1.21
ISRAEL	20	2,869	1.13

# Gazetteer Trials Newsletter

## Excels file **Gazetteer Trials: 2020-November-19.**

**Note 1:** We do not necessary know the location of the headquarter of each sponsor. You may have to search over Internet.

**Note 2:** All trials are in the planning phase, meaning that we do not yet know the location – country or countries – where the trial will be conducted.

But there will some information posted on clinicaltrials.gov as illustrated on the following pages.

Let us visit the ACOTEC trial – line seven in the Excel file – by clicking on the IDCTGOV link (Next page).

	A	B	C	D	E	F	G	H	I
1	IDCTGOV (Link)	SPONOSOR	AREA / DISEASE	TEST PRODUCT	STATUS	PHASE	SUBJECTS GLOBAL (N)	MIN AGE	MAX AGE
2	<a href="#">NCT04626297</a>	ELI LILLY	ALLERGY ECZEMA/DERMATITIS	DRUG	1. PLANNING	3	240	18 YEARS	55 YEARS
3	<a href="#">NCT04622735</a>	UNITHER	ANEST PAIN ACUTE	COMBINATION	1. PLANNING	3	321	18 YEARS	65 YEARS
4	<a href="#">NCT04630158</a>	NOVARTIS	ANEST PAIN CHRONIC	OTHER	1. PLANNING	2	150	18 YEARS	N/A
5	<a href="#">NCT04630067</a>	ASTRAZENECA	CARDIO CARDIOMYOP/FAILURE	DRUG	1. PLANNING	1	104	18 YEARS	75 YEARS
6	<a href="#">NCT04625764</a>	CYTOSORBENTS	CARDIO CORONARY/ISCHEMIC	PROCEDURE	1. PLANNING	NA	30	18 YEARS	N/A
7	<a href="#">NCT04626687</a>	ACOTEC	CARDIO CORONARY/ISCHEMIC	DEVICE	1. PLANNING	NA	230	18 YEARS	80 YEARS
8	<a href="#">NCT04627207</a>	CHONG KUN DANG	CARDIO DISEASE	DRUG	1. PLANNING	1	51	19 YEARS	54 YEARS
9	<a href="#">NCT04630704</a>	PEDRA	CARDIO HEART DISEASE	DEVICE	1. PLANNING		50	40 YEARS	90 YEARS
10	<a href="#">NCT04626245</a>	LIFESPAN	CARDIO HYPERTENSION	BEHAVIORAL	1. PLANNING	NA	150	18 YEARS	N/A
11	<a href="#">NCT04625660</a>	PQ BYPASS	CARDIO PERIPH VASC	DEVICE	1. PLANNING	NA	70	18 YEARS	90 YEARS
12	<a href="#">NCT04627870</a>	ACOTEC	CARDIO PERIPH VASC	DEVICE	1. PLANNING	NA	60	18 YEARS	80 YEARS
13	<a href="#">NCT04622644</a>	UMBRIA BIO.	CARDIO STROKE	DEVICE	1. PLANNING	NA	60	18 YEARS	N/A
14	<a href="#">NCT04628481</a>	DOMPE	ENDO DIABETES	DRUG	1. PLANNING	3	327	14 YEARS	45 YEARS
15	<a href="#">NCT04623957</a>	PANSATORI	ENT TINNITUS	DEVICE	1. PLANNING	NA	35	18 YEARS	N/A
16	<a href="#">NCT04624841</a>	HAMAD MEDICAL	GI BILIARY DISEASE	DRUG	1. PLANNING	4	80	18 YEARS	N/A
17	<a href="#">NCT04622358</a>	ADDPHARMA	GI ESOPHAGITIS/REFLUX	DRUG	1. PLANNING	1	40	19 YEARS	50 YEARS

# Gazetteer Trials Newsletter

## **Excels file *Gazetteer Trials: 2020-November-19.***

Let us visit the ACOTEC trial – see screen shot below (top of the clinicaltrials.gov listing).

The full name of the Sponsor is Acotec Scientific Co., Ltd.

We can use the full name and search for more details about the Sponsor over Internet such as drug pipeline and contact details. The best advice is to call the company. Email communication is not often successful.

As seen below Acotec Scientific Co., Ltd is probably located to China, and has an academic collaborator in Shanghai.

Let us check the contact details – next page.

**Sponsor:**

Acotec Scientific Co., Ltd

**Collaborator:**

Shanghai Tongji Hospital, Tongji University School of Medicine

**Information provided by (Responsible Party):**

Acotec Scientific Co., Ltd

# Gazetteer Trials Newsletter

## Excels file **Gazetteer Trials: 2020-November-19.**

Let us check the contact details.

Top of clinicaltrials.gov listing – *See Contacts and Locations.*

Click! (Next Page)

ClinicalTrials.gov Identifier: NCT04626687

Recruitment Status ⓘ : Not yet recruiting

First Posted ⓘ : November 12, 2020

Last Update Posted ⓘ : November 13, 2020

See [Contacts and Locations](#)



# Gazetteer Trials Newsletter

## Excels file **Gazetteer Trials: 2020-November-19.**

### Contacts

Contact: Xuebo Liu, MD 13801926702 [lxb70@hotmail.com](mailto:lxb70@hotmail.com)

### Sponsors and Collaborators

Acotec Scientific Co., Ltd

Shanghai Tongji Hospital, Tongji University School of Medicine

### Investigators

Principal Investigator: Xuebo Liu, MD Shanghai Tongji Hospital, Tongji University School of Medicine

### More Information

Responsible Party:	Acotec Scientific Co., Ltd
ClinicalTrials.gov Identifier:	<a href="#">NCT04626687</a> <a href="#">History of Changes</a>
Other Study ID Numbers:	ACOART paclitaxel SVD
First Posted:	November 12, 2020 <a href="#">Key Record Dates</a>
Last Update Posted:	November 13, 2020
Last Verified:	November 2020
Studies a U.S. FDA-regulated Drug Product:	No
Studies a U.S. FDA-regulated Device Product:	No

In this part of the listing we can identify sponsor contacts, collaborators and investigators.

An important finding - see end of the screen shot - is that the study on the Product is **not FDA-regulated**. This means that the trials will not – at least not initially - be conducted in the US.

# Gazetteer Trials Newsletter

## **Excels file *Gazetteer Trials: 2020-November-19.***

By checking over Internet - we found out that the company is located to Beijing.

*Founded in 2008 and located in Beijing Economic Technological Development Area, Acotec Scientific Co., Ltd. is a wholly foreign-owned enterprise integrating design, R&D, manufacturing and sales.*

*Our products are mainly used for vascular interventional treatment, including Drug Coated Balloon Catheter (DCB), Percutaneous Transluminal Angioplasty Balloon Catheter (PTA) etc.*

# Gazetteer Trials Newsletter

**Excels file [Gazetteer Trials: 2020-November-19](#).**

**Conclusion:** This trial will most certainly not be conducted in the US.

But still, the Sponsor is international despite of being located to Beijing.

Most Sponsors will eventually target the US market and must therefore obtain US FDA Approval.

It may thus be possible that future Sponsor collaborators are to be identified in the US.

Maybe it would be worth already now contacting the Sponsor and discuss the future development of their product(s), and any possible collaboration.

# Gazetteer Trials Newsletter

## Excels file **Gazetteer Trials: 2020-November-19.**

A 2<sup>nd</sup> example.

The first trial listed is with Elly Lilly as Sponsor – Eczema / Dermatitis phase III trial with a sample size of 240.

	A	B	C	D	E	F	G	H	I
1	<a href="#">IDCTGOV (Link)</a>	SPONOSOR	AREA / DISEASE	TEST PRODUCT	STATUS	PHASE	SUBJECTS GLOBAL (N)	MIN AGE	MAX AGE
2	<a href="#">NCT04626297</a>	ELI LILLY	ALLERGY ECZEMA/DERMATITIS	DRUG	1. PLANNING	3	240	18 YEARS	55 YEARS
3	<a href="#">NCT04622735</a>	UNITHER	ANEST PAIN ACUTE	COMBINATION	1. PLANNING	3	321	18 YEARS	65 YEARS
4	<a href="#">NCT04630158</a>	NOVARTIS	ANEST PAIN CHRONIC	OTHER	1. PLANNING	2	150	18 YEARS	N/A
5	<a href="#">NCT04630067</a>	ASTRAZENECA	CARDIO CARDIOMYOP/FAILURE	DRUG	1. PLANNING	1	104	18 YEARS	75 YEARS
6	<a href="#">NCT04625764</a>	CYTOSORBENTS	CARDIO CORONARY/ISCHEMIC	PROCEDURE	1. PLANNING	NA	30	18 YEARS	N/A
7	<a href="#">NCT04626687</a>	ACOTEC	CARDIO CORONARY/ISCHEMIC	DEVICE	1. PLANNING	NA	230	18 YEARS	80 YEARS
8	<a href="#">NCT04627207</a>	CHONG KUN DANG	CARDIO DISEASE	DRUG	1. PLANNING	1	51	19 YEARS	54 YEARS
9	<a href="#">NCT04630704</a>	PEDRA	CARDIO HEART DISEASE	DEVICE	1. PLANNING		50	40 YEARS	90 YEARS
10	<a href="#">NCT04626245</a>	LIFESPAN	CARDIO HYPERTENSION	BEHAVIORAL	1. PLANNING	NA	150	18 YEARS	N/A
11	<a href="#">NCT04625660</a>	PQ BYPASS	CARDIO PERIPH VASC	DEVICE	1. PLANNING	NA	70	18 YEARS	90 YEARS
12	<a href="#">NCT04627870</a>	ACOTEC	CARDIO PERIPH VASC	DEVICE	1. PLANNING	NA	60	18 YEARS	80 YEARS
13	<a href="#">NCT04622644</a>	UMBRIA BIO.	CARDIO STROKE	DEVICE	1. PLANNING	NA	60	18 YEARS	N/A
14	<a href="#">NCT04628481</a>	DOMPE	ENDO DIABETES	DRUG	1. PLANNING	3	327	14 YEARS	45 YEARS
15	<a href="#">NCT04623957</a>	PANSATORI	ENT TINNITUS	DEVICE	1. PLANNING	NA	35	18 YEARS	N/A
16	<a href="#">NCT04624841</a>	HAMAD MEDICAL	GI BILIARY DISEASE	DRUG	1. PLANNING	4	80	18 YEARS	N/A
17	<a href="#">NCT04622358</a>	ADDPHARMA	GI ESOPHAGITIS/REFLUX	DRUG	1. PLANNING	1	40	19 YEARS	50 YEARS


# Gazetteer Trials Newsletter

## Excels file **Gazetteer Trials: 2020-November-19.**

The first trial listed is with Elly Lilly as Sponsor – Eczema / Dermatitis phase III trial with a sample size of 240.

Below is the screen shot of first part of the clinicaltrials.gov listing for the trial.

- *Not yet recruiting*
- *First Posted November 12, 2020*
- Let us go to [Contacts and Locations](#)



# Gazetteer Trials Newsletter

## Excels file **Gazetteer Trials: 2020-November-19.**

The first trial listed is with Elly Lilly as Sponsor – Eczema / Dermatitis phase III trial with a sample size of 240.

- Contact details, 27 locations, Study Director information
- US FDA Regulated

### Contacts

Contact: There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 [Clinicaltrials.gov@lilly.com](mailto:Clinicaltrials.gov@lilly.com)

### Locations

▶ Show 27 study locations

### Sponsors and Collaborators

Eli Lilly and Company

### Investigators

Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company

Studies a U.S. FDA-regulated Drug Product:

Yes

Studies a U.S. FDA-regulated Device Product:

No

# Gazetteer Trials Newsletter

## Excels file **Gazetteer Trials: 2020-November-19.**

The first trial listed is with Elly Lilly as Sponsor – Eczema / Dermatitis phase III trial with a sample size of 240.

The trial is under planning, **but 27 sites have already been listed. All sites are US sites.**

**Contacts**  
Contact: There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 [Clin](#)

**Locations**  
▶ Show 27 study locations

**Sponsors and Collaborators**  
Eli Lilly and Company

**Investigators**  
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC)

▼ Hide 27 study locations

**United States, California**

- Wallace Medical Group, Inc.  
Beverly Hills, California, United States, 90211  
Principal Investigator: Paul Wallace
- First OC Dermatology  
Fountain Valley, California, United States, 92708  
Principal Investigator: Vivian Laquer
- Dermatology Research Associates  
Los Angeles, California, United States, 90045  
Principal Investigator: Howard Sofen
- TCR Medical Corporation  
San Diego, California, United States, 92123  
Contact 858-571-6800 ext 100  
Principal Investigator: Neal D Bhatia
- Southern California Dermatology, Inc.  
Santa Ana, California, United States, 92701  
Contact 714-474-2173  
Principal Investigator: Jennifer Soung

**United States, Colorado**

## End Comment

If time permit the study site should consider checking all trials that the Investigator is interested in.

Contacting Sponsor during the planning phase of the trial is known to be one of the few possible ways to be selected as a study site.

One advice - if possible – is to call the **local Sponsor's representative** – e.g. medical representative or medical director – and express interest in the trial.

This may not always be successful, but it will certainly be an important part of the marketing strategy of the Investigator / site.

Maybe the sponsor will consider listing Your site as a potential site – e.g. existing sites may redraw from the trial or the subject recruitment rate may be poor and additional sites will be needed.



# Investigator Gazetteer

Thank you!